Alemtuzumab Articles
Sanofi moves on Lemtrada; Novartis Indian patent case
21 August 2012
Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif
24 October 2011
Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq
12 July 2011
Sanofi-Aventis confirms it is considering CVR-based deal regarding takeover of Genzyme
10 January 2011
Genzyme touts value of alemtuzumab for MS in bid to get Sanofi to raise its hostile offer
21 December 2010
Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest
18 October 2010
Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019
13 July 2010
US FDA approves GlaxoSmithKline’s Jalyn for symptomatic BPH; fast tracks Genzyme’s MS drug alemtuzumab
15 June 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
22 January 2010
New guidelines for blood cancer therapy
23 March 2009
BLA submitted for GSK and Genmab's Arzerra
9 February 2009
Promising Ph II data for Genzyme/Bayer's alemtuzumab
27 October 2008
CLARIFICATION: Genzyme's Campath Ph II trial results
27 October 2008
Genzyme's Campath does well in Ph II CLL trial
20 October 2008
Ofatumumab sees positive Ph III CLL data
11 August 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Bayer's MabCampath cleared for CLL by EC
14 January 2008
132 patients enter pivotal study of Genmab CLL drug
10 December 2007
CHMP advocates MabCampath approval
29 October 2007
Stock Commentary - New York - week to October 15, 2007
22 October 2007
Stock Commentary - Europe - week to October 15, 2007
22 October 2007
Alemtuzumab cuts relapse risk in RRMS
22 October 2007
FDA approves Campath as single agent for B-CLL
1 October 2007
Genzyme/Bayer start Ph III alemtuzumab program
1 October 2007
Strong Ph II data on Genzyme/Bayer's MS drug
14 May 2007
Genzyme/Bayer file for Campath label expansion
16 April 2007
Japan's MHLW proposes "drug lag" solution
5 February 2007
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
Genzyme's 2nd-qtr 2006 revenue rises 19%
24 July 2006
BTG's fiscal 2005/06 income rises 31%
5 June 2006
Genmab's HuMax-CD20 enters pivotal Ph III trial
5 June 2006
Stock Commentary - New York week to May 22, 2006
29 May 2006
Genzyme's Campath for MS subject of FDA health warning
12 December 2005
Genzyme completes ILEX Oncology buy
10 January 2005
ILEX' loss grows for third quarter
1 November 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
Stock Commentary - New York
8 March 2004
Genzyme to buy ILEX for $1 billion
8 March 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Schering AG reports 6% "organic" sales growth for 2003
9 February 2004
Ilex may extend Campath license with BTG
10 March 2003
Schering AG CEO optimistic about firm's future prospects
22 April 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Ilex says Campath sales reach $27.1 million
11 February 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Millennium licenses cancer compounds from Xenova
7 January 2002
Millennium licenses cancer compounds from Xenova
17 December 2001
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Ilex to pay $140M for Campath rights
31 October 2001
Schering's Campath shows potential for treatment of T-PLL
3 October 2001
Schering AG raises earnings expectations
27 July 2001
Millennium net loss reaches $30.7 million
19 July 2001
M&I's MabCampath is approved by EMEA
12 July 2001
Stock Commentary - Europe
17 May 2001
MabCampath nears EU approval for CLL
30 March 2001
Schering AG to "grow faster than market"
16 March 2001
Stock Commentary - New York
22 February 2001
Campath approval delayed in USA
21 February 2001
Oral Fludara launched in first market
22 January 2001
BTG's Campath nears approval in USA
15 December 2000
Berlex commences OncoLym trial in B cell lymphoma
21 September 2000
Stock Commentary New York
18 May 2000
Millennium Pharma confident about future
20 April 2000
Schering AG sales up 9% for 1st nine months
11 November 1999
Millennium Pharmaceuticals set to buy LeukoSite for $635 million
18 October 1999
Schering AG signs deal for Campath
25 August 1999
-LeukoSite and ILEX meet with FDA over Campath
8 April 1999
LeukoSite Lead Product May Be On Market By 2000
28 May 1998
Oncology And LeukoSite Form JV For CLL
19 May 1997
Burroughs Wellcome Outlook Reviewed
19 December 1994
Wellcome Stops Campath-1H Development
3 October 1994
CAMPATH-1H AND SYSTEMIC VASCULITIS
5 July 1993
WELLCOME REFOCUSING R&D EFFORTS
10 May 1993
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
WELLCOME PRETAX PROFITS RISE 25%
2 November 1992
ANTIBODY THERAPY FOR ARTHRITIS: PHASE I STUDY
5 October 1992
WELLCOME ACQUISITION
5 October 1992
Europe: Stock Commentary
8 June 1992
Showing 1-93 of 93 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
